Thromb Haemost 1962; 07(03): 499-506
DOI: 10.1055/s-0038-1655399
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Hemostatic Effect of Adona (AC-17)

Chr. F Borchgrevink
1   Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)
,
Ragna Fölling Elgjo
1   Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)
,
K Hattel
1   Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)
,
P. F Hjort
1   Institute for Thrombosis Research, University Hospital, Rikshospitalet, Oslo, Norway (Head: Prof. P. A. Owren) and Vår Frues Hospital, Oslo, Norway (Head: Dr. R. Andersen)
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

Summary

In normal individuals 50 mg Adona (AC-17) intravenously increased capillary resistance, and slightly shortened the bleeding time. No effect was observed on coagulation or platelets.

In patients undergoing prostatic surgery the drug seemed to reduce the blood loss during the operation.

50 mg Adona (AC-17) was given to 11 patients with a prolonged bleeding time of various causes, and to 8 patients with a positive tourniquet test. No effect could be demonstrated. However, the drug may be of value in some patients with acquired, ill-defined, presumably vascular diseases.